In this episode of “Blood Cancer Talks,” the hosts are joined by Martin Kaiser, MD, of the Institute of Cancer Research and the Royal Marsden Hospital. Dr. Kaiser and the hosts discuss strategies to identify and treat patients with newly diagnosed high-risk multiple myeloma (MM).
They discuss key data from the phase II OPTIMUM trial, how to predict ultrahigh-risk myeloma by molecular profiling and how cytogenetic features shape risk.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM. Additionally, they discuss the outcomes of patients with a double-hit signature who were in the MASTER and GRIFFIN trials, as well as the impact of autologous hemopoietic stem cell transplant on decreasing measurable residual disease burden in high-risk MM.
This podcast originally appeared on Blood Cancer Talks.